Malignant mesothelioma

Active Research Protocols

  1. 08-C-0026 – A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Epithelial Pleural Mesothelioma
  2. 10-C-0146 – Phase II Study of IMC-A12 in Patients with Mesothelioma Who Have Been Previously Treated with Chemotherapy
  3. 11-C-0160 – A Pilot Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients with Mesothelioma
  4. 12-C-0170 – A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS 207 in Combination with Pemetrexed and Cisplatin as Front-Line Therapy in Adults with Malignant Pleural Mesothelioma
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014